Description

Mirtazapine Tablet IP 7.5 Mg – MITACREST 7.5 Tablets
Composition  –Mirtazapine 7.5 mg

Description:
MITRACREST 7.5 contains Mirtazapine Tablet IP 7.5 mg, a noradrenergic and specific serotonergic antidepressant (NaSSA) indicated for the treatment of major depressive disorder (MDD). It works by blocking alpha-2 adrenergic autoreceptors and heteroreceptors, leading to enhancing the release of both norepinephrine and serotonin in the brain. Additionally, its antagonism at 5-HT2 and 5-HT3 receptors contributes to improved mood, reduced anxiety, and better sleep quality.
The 7.5 mg strength serves as the ideal initiation dose, particularly in elderly patients, anxious individuals, and those with sleep disturbances, allowing the body to adjust before gradual dose escalation.

Key Points
NaSSA Mechanism — Dual enhancement of norepinephrine and serotonin without reuptake inhibition
Lowest Initiation Dose — 7.5 mg is ideal for starting therapy, especially in sensitive and elderly patients
Improves Sleep Quality — Strong sedative and anxiolytic properties beneficial in depression with insomnia
Reduces Anxiety — Effective in managing anxiety symptoms co-existing with depression
Better GI Tolerability — 5-HT3 antagonism reduces nausea and GI side effects common with SSRIs
Appetite Stimulation — Beneficial in depressed patients with poor appetite or weight loss
Alternative to SSRIs/SNRIs — Suitable for patients with inadequate response or intolerance to first-line antidepressants

Targeted Specialties
Psychiatry
Neurology
General Physician & Internal Medicine

Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.